Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Wake Forest University Health Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Thirty patients will be enrolled, with the expectation that 20-25 will complete all follow-up measures.
The purpose of this trial is to evaluate the feasibility and adherence to a home-based 12 week exercise intervention in mCRPC patients receiving ADT. It will also examine if a home-based exercise intervention can improve muscle strength, body composition, physical function, cardiopulmonary function fatigue, and patient reported outcomes (fatigue, depression, quality of life (QoL)).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Home-based Exercise | Experimental | The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Home-based exercise | Behavioral | The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. | To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing. | 12 weeks after baseline testing |
| Measure | Description | Time Frame |
|---|---|---|
| Adherence to the Intervention | To report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence. Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Any condition that causes severe pain with exertion.
History of bone fractures.
Active cardiovascular disease including any of the following:
Acute or chronic respiratory disease that is severe enough to compromise the ability of the participant to safely engage in exercise training protocol.
Acute or chronic bone/joint/muscular abnormalities compromising their ability to exercise.
Neurological conditions that affect balance and, or muscle strength.
Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erik D Hanson, PhD | UNC-Chapel Hill | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill | Chapel Hill | North Carolina | 27599 | United States | ||
Both sites (UNC and WF) are adding and storing data on a secure, centralized server. No individual data will be made available to protect the identity of the patients in the trial.
Not provided
Not provided
Not provided
Not provided
62 subjects were referred to the study. Of this, 40 did not participate or qualify for the study. 22 subjects were consented and 16 completed all aspects of the trial.
Subjects were recruited from 4/16/2017 through 12/5/2019 from referrals from medical oncologists from three institutions.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Home-based Exercise | The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. Home-based exercise: The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Data were reported only on those subjects who completed the intervention and performed testing at baseline and post intervention.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Home-based Exercise | The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. Home-based exercise: The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. | To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing. | All participants in the trial. | Posted | Count of Participants | Participants | 12 weeks after baseline testing |
|
12 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Home-based Exercise | The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. Home-based exercise: The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| calcium pyrophosphate deposition disease | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Erik Hanson, PhD | University of North Carolina at Chapel Hill | 19199620816 | edhanson@email.unc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 23, 2019 | Dec 10, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
Single-arm study with ~30 men being recruited and 20-25 who complete all aspects of the study.
Not provided
Not provided
Not provided
Not provided
|
| 12 weeks after baseline testing |
| Physical Function: 6m Walk | The time to complete (in sec) the 6m rapid walk test will be performed. | 12 weeks after baseline testing |
| Physical Function: Timed Up and Go | The time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance. | 12 weeks after baseline testing |
| Physical Function: Stair Climb | The time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance. | 12 weeks after baseline testing |
| Physical Function: 400m Walk | The time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14). | 12 weeks after baseline testing |
| Patient Reported Outcomes: Fatigue | Fatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue). | 12 weeks after baseline testing |
| Patient Reported Outcomes: Quality of Life | Quality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL. | 12 weeks after baseline testing |
| Patient Reported Outcomes: Depression | Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. | 12 weeks after baseline testing |
| Patient Reported Outcomes: Anxiety | Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. | 12 weeks after baseline testing |
| Muscle Size (Cross-sectional Area) | Muscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. | 12 weeks after baseline testing |
| Muscle Quality | Muscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality. | 12 weeks after baseline testing |
| Chest Press Maximal Strength | Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. | 12 weeks after baseline testing |
| Chest Press Muscle Endurance | Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. | 12 weeks after baseline testing |
| Leg Press Maximal Strength | Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. | 12 weeks after baseline testing |
| Leg Press Muscle Endurance | Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. | 12 weeks after baseline testing |
| Cardiopulmonary Function | To report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness. | 12 weeks after baseline testing |
| Lean Mass | To report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. | 12 weeks after baseline testing |
| Fat Mass | To report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. | 12 weeks after baseline testing |
| Percent Body Fat | To report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. | 12 weeks after baseline testing |
| Comprehensive Cancer Center, Wake Forest Baptist Health |
| Winston-Salem |
| North Carolina |
| 27103 |
| United States |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Height | Mean | Standard Deviation | cm |
|
| Mass | Mean | Standard Deviation | kg |
|
| Body Mass Index | Mean | Standard Deviation | kg/m^2 |
|
| Duration of Androgen Deprivation Therapy (ADT) | Mean | Standard Deviation | days |
|
| Previous Prostatectomy | Count of Participants | Participants |
|
| Previous Radiotherapy | Count of Participants | Participants |
|
| Previous Chemotherapy | Count of Participants | Participants |
|
| Time since Chemotherapy | Mean | Standard Deviation | months |
|
|
|
| Secondary | Adherence to the Intervention | To report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence. Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed. | This analysis was restricted to subjects who completed the intervention and returned their training logs. | Posted | Number | percentage of total sessions prescribed | 12 weeks after baseline testing |
|
|
|
| Secondary | Physical Function: 6m Walk | The time to complete (in sec) the 6m rapid walk test will be performed. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial. | Posted | Mean | Standard Deviation | seconds | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Physical Function: Timed Up and Go | The time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial. | Posted | Mean | Standard Deviation | seconds | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Physical Function: Stair Climb | The time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial. | Posted | Mean | Standard Deviation | seconds | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Physical Function: 400m Walk | The time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14). | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial. | Posted | Mean | Standard Deviation | seconds | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Patient Reported Outcomes: Fatigue | Fatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue). | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires. | Posted | Mean | Standard Deviation | score on a scale | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Patient Reported Outcomes: Quality of Life | Quality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires. | Posted | Mean | Standard Deviation | score on a scale | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Patient Reported Outcomes: Depression | Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires. | Posted | Mean | Standard Deviation | score on a scale | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Patient Reported Outcomes: Anxiety | Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires. | Posted | Mean | Standard Deviation | score on a scale | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Muscle Size (Cross-sectional Area) | Muscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the University of North Carolina (UNC) site only. Equipment to perform this analysis at the Wake Forest site was not available. | Posted | Mean | Standard Deviation | cm^2 | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Muscle Quality | Muscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site. | Posted | Mean | Standard Deviation | unitless | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Chest Press Maximal Strength | Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site. | Posted | Mean | Standard Deviation | kg | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Chest Press Muscle Endurance | Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site. | Posted | Mean | Standard Deviation | number of repetitions completed | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Leg Press Maximal Strength | Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site. | Posted | Mean | Standard Deviation | kg | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Leg Press Muscle Endurance | Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site. | Posted | Mean | Standard Deviation | number of repetitions completed | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Cardiopulmonary Function | To report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial. | Posted | Mean | Standard Deviation | mL/kg/min | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Lean Mass | To report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and the body composition scans. | Posted | Mean | Standard Deviation | kg | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Fat Mass | To report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and completed the body composition scans. | Posted | Mean | Standard Deviation | kg | 12 weeks after baseline testing |
|
|
|
|
| Secondary | Percent Body Fat | To report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. | Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and the body composition scans. | Posted | Mean | Standard Deviation | percentage of total body mass | 12 weeks after baseline testing |
|
|
|
|
| 0 |
| 22 |
| 0 |
| 22 |
| 1 |
| 22 |
Not provided
Not provided
Not provided
| Title | Measurements |
|---|---|
|